Sanofi | LinkedIn (original) (raw)
À propos
We are Sanofi, an innovative global healthcare company. We chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms
Secteur
Fabrication de produits pharmaceutiques
Taille de l’entreprise
+ de 10 000 employés
Siège social
Paris, France
Type
Société cotée en bourse
Domaines
vaccines, rare diseases, rare blood disorders, neurology, immunology, oncology, diabetes, cardiovascular diseases et consumer healthcare
Lieux
- Principal
46 Avenue de la Grande-Armée
75017 Paris, France, FR
Obtenir l’itinéraire - 75300 Karachi, Sindh, PK
Obtenir l’itinéraire - 11 Beach Rd
Singapore, Singapore, SG
Obtenir l’itinéraire - Francisco Garcia Cortinas 2357
11300 Montevideo, UY
Obtenir l’itinéraire - 1 Discovery Dr
18370 Swiftwater, PA, US
Obtenir l’itinéraire - Praca Floriano, 19
20031-050 Rio de Janeiro, RJ, BR
Obtenir l’itinéraire - Calle Aquilino de la Guardia & Calle 47
Panama City, Panama, PA
Obtenir l’itinéraire - 32nd St
Taguig City, National Capital Region, PH
Obtenir l’itinéraire - Los Sauces
15036 San Isidro, Lima, PE
Obtenir l’itinéraire - Avenida das Nacoes Unidas
04794-000 Sao Paulo, SP, BR
Obtenir l’itinéraire - Lützowstraße 107
10785 Berlin, BE, DE
Obtenir l’itinéraire
Employés chez Sanofi
Nouvelles
- Today the FDA accepted the resubmission of our application for an investigational medicine for chronic spontaneous urticaria (CSU), an inflammatory skin disease driven in part by type 2 inflammation. We remain committed to bringing a new option for people suffering from this condition which causes sudden and debilitating hives and recurring itch. Learn more: http://spkl.io/6042fVJ2E Regeneron
- The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) recommended the approval of our #MultipleMyeloma combination therapy. If approved, this would be the first therapy in its class available in the EU, in combination with a current standard-of-care regimen, for newly diagnosed multiple myeloma patients who are transplant-ineligible. Read our press release: https://lnkd.in/dnp6T5eM
- How can we harness the immune system to fight type 1 #diabetes? Learn more about how Sanofi is using immunoscience to develop new treatments that stop the immune system from attacking insulin-producing cells, possibly before T1D symptoms even appear: http://spkl.io/6043fpseU
- With the power of #AI, we’re discovering new ways to effectively harness the immune system and accelerate the development of new treatments for complex diseases. In a recent article published in WIRED, our visionary R&D leaders - Houman Ashrafian, Emmanuel Frenehard, and Helen Merianos - share how our approach to AI-powered immunoscience could unlock new possibilities in healthcare and deliver potentially life-changing therapies to patients faster than ever before. Read the article to learn more 👉 http://spkl.io/6049frdJZ #TransformingCare #Immunoscience
- From asthma to COPD, allergies to other inflammatory conditions, the impacts of climate change on immune-driven diseases are evident. In a new Project Syndicate article, our CEO Paul Hudson discusses how global warming is increasing the prevalence and exacerbation of respiratory diseases and shares insights on strategies to help address the consequences suffered by the most vulnerable populations. Read more: http://spkl.io/6044fTlli #ClimateChange #AI
- The European Commission has approved the first and only medicine for children aged 1-11 with eosinophilic esophagitis (#EoE). We’re proud to offer a treatment option that has the potential to improve the standard of care for children living with this chronic, progressive disease. Learn more about the news: https://lnkd.in/eUtjGA3b Regeneron
- Sanofi a republié ceci
Global Vaccines Public Affairs Head
1 sem.
Did you know Respiratory Syncytial Virus (#RSV) can turn a family's world upside down in just a few days? For most babies, RSV disease usually causes mild, cold-like symptoms. But in some cases, it can lead to more serious illnesses. As we mark #RSVAwarenessWeek in Europe, it's time to recognize the unseen battles that parents may face when a child contracts a severe form of RSV disease. The sleepless nights, the worry and the struggle to keep up with everyday life: it’s a tough reality. The #ResQFamily study by EFCNI - European Foundation for the Care of Newborn Infants uncovers just how families are managing these challenges. Curious about what they found? Read the full report: https://lnkd.in/e9itnGwm - What does it take to create life-changing treatments? For Lana Vishneva, it’s all about connecting the dots. Just like creating a mosaic, Lana understands how individual pieces come together to form something meaningful ✨ 👩🔬 As one of our Product Managers, she brings our vision to life by blending research, patient insights, and team collaboration to develop treatments. Connecting with patients, listening to their stories, and witnessing the real difference her work makes is what drives her every day. Learn more about Lana's journey: http://spkl.io/6048fr65Y #WeNeverSettle #IgnitingPotential #RareDisease